Veracyte SEC Filings

Form 144 notice for Veracyte, Inc. (VCYT) reporting a proposed sale of 2,283 common shares, with an aggregate market value of $75,864.09, scheduled approximately for 09/19/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The shares were acquired as restricted stock units on 06/02/2025 from the issuer and were fully issued on that date. The filer certifies there are no undisclosed material adverse facts and reports no other sales by the same person in the past three months. The filing provides basic transactional details but does not state the seller's identity or motivation for the sale.

Marc Stapley, Chief Executive Officer and Director of Veracyte, Inc. (VCYT), sold 7,667 shares of the company's common stock on 09/04/2025 under a pre-established Rule 10b5-1 trading plan adopted on 09/13/2024. The transaction was reported at a weighted-average sale price of $30.4073, with individual sale prices ranging from $30.22 to $30.66. After the reported sale, the filing shows Mr. Stapley beneficially owns 334,185 shares. The Form 4 was executed by an attorney-in-fact and includes customary disclosure that detailed per-price share breakdowns are available upon request.

Rebecca Chambers, Chief Financial Officer of Veracyte, Inc. (VCYT), reported a Form 4 disclosing that on 09/02/2025 5,371 shares of Common Stock were withheld to satisfy tax withholding obligations related to the vesting of restricted stock units. The filing shows 133,158 shares of Common Stock beneficially owned by the reporting person after the transaction. The transaction code is noted as F and the per-share price listed is $30.11, with the filer confirming the withholding was not a sale but a tax-related retention of shares.

Annie McGuire, SVP and General Counsel of Veracyte, Inc. (VCYT), reported that 3,507 shares of common stock were withheld on 09/02/2025 to satisfy tax withholding tied to the vesting of restricted stock units; this withholding is not a sale and was executed at a per-share price of $30.11. After the withholding, McGuire beneficially owned 93,882 shares, which includes 386 shares purchased on 07/31/2025 under the company’s Employee Stock Purchase Plan. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/04/2025.

Marc Stapley, who is listed as both Chief Executive Officer and a director of Veracyte, Inc. (VCYT), reported a non-sale withholding of 7,914 shares of common stock on 09/02/2025 at an attributable price of $30.11 per share. The withholding satisfied tax obligations arising from the vesting of restricted stock units and therefore was not a market sale. After the transaction Stapley beneficially owned 341,852 shares, which includes 529 shares purchased on 07/31/2025 under the company’s Employee Stock Purchase Plan. The Form 4 was signed by an attorney-in-fact on 09/04/2025.

Veracyte insider Phillip G. Febbo reported a non-sale disposition of 2,955 shares of common stock on 09/02/2025. The transaction reflects shares withheld to satisfy tax withholding obligations related to the vesting of restricted stock units, executed at a reported price of $30.11 per share. After the withholding, the reporting person beneficially owns 100,790 shares. The Form 4 was signed by an attorney-in-fact on 09/04/2025 and identifies Febbo as the company’s Chief Scientific & Medical Officer and an officer of Veracyte (VCYT).

John Leite, Chief Commercial Officer-CLIA of Veracyte, Inc. (VCYT), reported a transaction dated 09/02/2025 in which 2,902 shares of the company's common stock were withheld at a price of $30.11 to satisfy tax withholding obligations related to the vesting of restricted stock units. The filing clarifies that the withheld shares do not represent a sale. After the withholding, the reporting person beneficially owned 91,638 shares, held directly. The Form 4 was signed by an attorney-in-fact, Jonathan Wygant, on 09/04/2025. The form indicates the filing was made by one reporting person and identifies the reporting persons address as South San Francisco, CA.

Jonathan Wygant, Veracyte (VCYT) reporting person, disclosed a non-sale disposition on 09/02/2025 in which 1,648 shares of common stock were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock units; the transaction is reported at a per-share value of $30.11. The filing clarifies this withholding does not represent a sale.

After the withholding, the reporting person beneficially owns 46,779 shares, which includes 512 shares purchased on July 30, 2025 under the company ESPP. The reporting person is identified as an officer with the title VP, Chief Accounting Officer.

Veracyte, Inc. (VCYT) notice reports a proposed sale of 7,667 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $234,763.54 and an approximate sale date of 09/04/2025. The filing shows the shares were acquired as Restricted Stock Units from the issuer on 09/02/2025 and payment/vesting is recorded as 09/02/2025. The issuer's total shares outstanding is listed as 78,671,588. The filer reports no securities sold by the same person in the past three months. The notice includes the required representation that the seller does not possess any undisclosed material adverse information regarding the issuer.

This Schedule 13G/A shows Artisan Partners entities beneficially own 6,321,775 shares of Veracyte common stock, equal to 8.1% of the class based on 78,314,611 shares outstanding. The reported position reflects shared voting power of 5,220,102 and shared dispositive power over the full 6,321,775 shares, with no sole voting or dispositive power asserted. The filing states the shares are held for discretionary clients of the adviser and were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control. The document names the reporting entities within the Artisan Partners group.